Clementia completes patient enrolment in Phase II trial of palovarotene to treat FOP

Canada-based Clementia Pharmaceuticals has completed patient enrolment in its Phase II clinical trial of palovarotene, a retinoic acid receptor gamma agonist, to treat fibrodysplasia ossificans progressiva (FOP).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news